Agile Therapeutics ROA 2013-2023 | AGRX
Current and historical return on assets (ROA) values for Agile Therapeutics (AGRX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Agile Therapeutics ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2023-12-31 |
$-0.01B |
$0.01B |
-116.67% |
| 2023-09-30 |
$-0.01B |
$0.01B |
-107.69% |
| 2023-06-30 |
$-0.02B |
$0.01B |
-128.81% |
| 2023-03-31 |
$-0.02B |
$0.01B |
-101.27% |
| 2022-12-31 |
$-0.03B |
$0.01B |
-106.38% |
| 2022-09-30 |
$-0.04B |
$0.02B |
-137.82% |
| 2022-06-30 |
$-0.05B |
$0.03B |
-150.72% |
| 2022-03-31 |
$-0.07B |
$0.03B |
-165.61% |
| 2021-12-31 |
$-0.07B |
$0.04B |
-154.01% |
| 2021-09-30 |
$-0.07B |
$0.04B |
-126.70% |
| 2021-06-30 |
$-0.07B |
$0.05B |
-101.10% |
| 2021-03-31 |
$-0.06B |
$0.06B |
-76.54% |
| 2020-12-31 |
$-0.05B |
$0.07B |
-56.68% |
| 2020-09-30 |
$-0.04B |
$0.09B |
-46.72% |
| 2020-06-30 |
$-0.03B |
$0.10B |
-39.19% |
| 2020-03-31 |
$-0.02B |
$0.11B |
-38.53% |
| 2019-12-31 |
$-0.02B |
$0.05B |
-53.33% |
| 2019-09-30 |
$-0.02B |
$0.03B |
-59.81% |
| 2019-06-30 |
$-0.02B |
$0.03B |
-60.95% |
| 2019-03-31 |
$-0.02B |
$0.03B |
-61.54% |
| 2018-12-31 |
$-0.02B |
$0.02B |
-59.70% |
| 2018-09-30 |
$-0.02B |
$0.03B |
-53.99% |
| 2018-06-30 |
$-0.03B |
$0.04B |
-52.91% |
| 2018-03-31 |
$-0.03B |
$0.04B |
-54.27% |
| 2017-12-31 |
$-0.03B |
$0.05B |
-52.58% |
| 2017-09-30 |
$-0.03B |
$0.06B |
-47.79% |
| 2017-06-30 |
$-0.03B |
$0.05B |
-47.66% |
| 2017-03-31 |
$-0.03B |
$0.06B |
-44.27% |
| 2016-12-31 |
$-0.03B |
$0.06B |
-39.16% |
| 2016-09-30 |
$-0.03B |
$0.07B |
-39.71% |
| 2016-06-30 |
$-0.03B |
$0.07B |
-43.08% |
| 2016-03-31 |
$-0.03B |
$0.08B |
-45.16% |
| 2015-12-31 |
$-0.03B |
$0.05B |
-50.85% |
| 2015-09-30 |
$-0.03B |
$0.06B |
-53.11% |
| 2015-06-30 |
$-0.03B |
$0.06B |
-46.96% |
| 2015-03-31 |
$-0.03B |
$0.07B |
-39.84% |
| 2014-12-31 |
$-0.02B |
$0.06B |
-35.16% |
| 2014-06-30 |
$-0.01B |
$0.07B |
-48.48% |
| 2014-03-31 |
$-0.01B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
